alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 582.1748 Sodium caseinate. ( a ) *Product.* Sodium caseinate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
<PAGE>

                                                                    Exhibit 21.1


                              LIST OF SUBSIDIARIES

<TABLE>
<CAPTION>

                                                            Jurisdiction             Percent Owned
Name of Subsidiary                                        of Incorporation           by Registrant
------------------                                        ----------------           -------------
<S>                                                         <C>                          <C>
ACTIVE

NUR Media Solutions S.A.                                       Belgium                   100%

NUR Europe S.A.                                                Belgium                   100%

NUR America Inc.                                              Delaware                   100%

NUR Macroprinters (Shanghai) Co., Ltd.                          China                    100%

NUR Pro Engineering Ltd.                                       Israel                     50%

Stillachem S.A.                                                Belgium                  50.1%

NUR Asia Pacific Ltd.                                         Hong Kong                  100%

INACTIVE

NUR Middle East & Africa Ltd.                                  Israel                    100%

NUR Hungaria KFT (1)                                           Hungary                   100%

Good-Lux S.A. (1)                                            Luxembourg                  100%

M.B.T. (NUR) Industries Ltd.                                   Israel                    100%

NUR Print Technologies (1993) Ltd.                             Israel                    100%

</TABLE>



-------------------

(1)  Represents the percentages of ownership of NUR Media Solutions S.A. in
     these subsidiaries.
# C_2015081EN.01000901.xml

| 9.3.2015 | EN | Official Journal of the European Union | C 81/9 |
| --- | --- | --- | --- |

9.3.2015

EN

Official Journal of the European Union

C 81/9

---

Request for a preliminary ruling from the Korkein oikeus (Finland) lodged on 30 December 2014 — Virpi Komu, Hanna Ruotsalainen, Ritva Komu v Pekka Komu, Jelena Komu

(Case C-605/14)

(2015/C 081/11)

Language of the case: Finnish

Referring court

Referring court

Korkein oikeus

Parties to the main proceedings

Parties to the main proceedings

Appellants: Virpi Komu, Hanna Ruotsalainen, Ritva Komu

Appellants:

Respondents: Pekka Komu, Jelena Komu

Respondents:

Question referred

Question referred

Is Article 22(1) of Council Regulation (EC) No 44/2001 (1) on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters to be interpreted as meaning that in a case in which some of the co-owners of immoveable property apply for the property to be sold for the purpose of the dissolution of the co-ownership relationship and for the trustee to carry out the sale is a question concerning rights in rem in immovable property?

1

in rem

---

(1)  OJ 2001 L 12, p. 1.

1

---
Exhibit 32.1





CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Annual Report of Hemispherx Biopharma, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William A. Carter, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:





(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.





/s/ William A. CarterWilliam A. Carter, M.D.Chief Executive OfficerMarch 28, 2011
[Federal Register Volume 75, Number 41 (Wednesday, March 3, 2010)]
[Notices]
[Page 9614]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4439]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated October 16, 2009, and published in the Federal 
Register on October 28, 2009 (74 FR 55584), Clinical Supplies 
Management, 342 42nd Street South, Fargo, North Dakota 58103, made 
application to the Drug Enforcement Administration (DEA) to be 
registered as an importer of Poppy Straw Concentrate (9670), a basic 
class of controlled substance listed in schedule II.
    The company plans to import an ointment for the treatment of wounds 
which contains trace amounts of controlled substances normally found in 
poppy straw concentrate which will be packaged and labeled for clinical 
trials.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and Sec.  952(a), and determined that 
the registration of Clinical Supplies Management to import the basic 
class of controlled substance is consistent with the public interest, 
and with United States obligations under international treaties, 
conventions, or protocols in effect on May 1, 1971, at this time. DEA 
has investigated Clinical Supplies Management to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 952(a) and Sec.  958(a), and 
in accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic class of controlled substance 
listed.

    Dated: February 24, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-4439 Filed 3-2-10; 8:45 am]
BILLING CODE 4410-09-P
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR 9 MONTHS ENDING SEPTEMBER 27,
1998 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10Q FOR THE
QUARTER ENDED SEPTEMBER 27, 1998.
</LEGEND>
<CIK> 0000813856
<NAME> ???????
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-27-1998
<PERIOD-START>                             DEC-29-1997
<PERIOD-END>                               SEP-27-1998
<CASH>                                          18,787
<SECURITIES>                                         0
<RECEIVABLES>                                    6,774
<ALLOWANCES>                                         0
<INVENTORY>                                      4,196
<CURRENT-ASSETS>                                33,505
<PP&E>                                         264,089
<DEPRECIATION>                                  83,742
<TOTAL-ASSETS>                                 274,089
<CURRENT-LIABILITIES>                          101,847
<BONDS>                                        215,775
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            10
<OTHER-SE>                                    (48,098)
<TOTAL-LIABILITY-AND-EQUITY>                   274,089
<SALES>                                        348,694
<TOTAL-REVENUES>                               348,694
<CGS>                                           93,288
<TOTAL-COSTS>                                  352,351
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              17,937
<INCOME-PRETAX>                               (21,594)
<INCOME-TAX>                                       300
<INCOME-CONTINUING>                           (21,894)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (21,894)
<EPS-PRIMARY>                                    (.18)
<EPS-DILUTED>                                    (.18)
        

</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel; Web-Enabled Cognitive/Neuropsychological Evaluation System (4411)                    

*Date:*                         March 30, 2010.                    

*Time:*                         1:30 p.m. to 3:30 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call)                    

*Contact Person:*                         Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401 (301) 435-1439,                         *lf33c.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: February 19, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4039 Filed 3-2-10; 8:45 am]

BILLING CODE 4140-01-M
I 

118TH CONGRESS 

2D SESSION H. R. 7619 

To require the Secretary of Health and Human Services to issue guidance 

to States on strategies under Medicaid and CHIP to increase mental 

health and substance use disorder care provider education, training, 

recruitment, and retention. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 11, 2024 

Mr. NEGUSE (for himself and Mr. ZINKE) introduced the following bill; which 

was referred to the Committee on Energy and Commerce 

A BILL 

To require the Secretary of Health and Human Services 

to issue guidance to States on strategies under Medicaid 

and CHIP to increase mental health and substance use 

disorder care provider education, training, recruitment, 

and retention. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Expand the Behavioral 

5 Health Workforce Now Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7619 IH

1 SEC. 2. GUIDANCE TO STATES ON STRATEGIES UNDER 

2 MEDICAID AND CHIP TO INCREASE MENTAL 

3 HEALTH AND SUBSTANCE USE DISORDER 

4 CARE PROVIDER EDUCATION, TRAINING, RE5 CRUITMENT, AND RETENTION. 

6 Not later than 12 months after the date of enactment 

7 of this Act, the Secretary of Health and Human Services 

8 shall issue guidance to States on strategies under Med9 icaid and CHIP to increase education, training, recruit10 ment, and retention of mental health and substance use 

11 disorder care providers that participate in Medicaid or 

12 CHIP, with a focus on improving the capacity of the men13 tal health and substance use disorder care workforce in 

14 rural and underserved areas. Such guidance shall include, 

15 and not be limited to, strategies on how States may utilize 

16 waivers under section 1115 of the Social Security Act (42 

17 U.S.C. 1315) and authorities under titles XIX and XXI 

18 of such Act (42 U.S.C. 1396 et seq., 1397aa et seq.) for 

19 such purposes. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
Order entered October 30, 2017

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-17-00838-CR

CARL LEVON BURNS, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the 195th Judicial District Court

Dallas County, Texas

Trial Court Cause No. F16-76243-N

ORDER

Before the Court is appellant’s October 26, 2017 motion for an extension of time to file

his brief. We GRANT the motion to the extent we ORDER appellant’s brief filed within thirty 

days from the date of this order. 

/s/ ADA BROWN 

JUSTICE
# EXHIBIT 99

Exhibit 99  Certification Pursuant to Section 1350 of Chapter 63 of
    Title 18 of the United States Code

I,
Shawn OBrien, the Chief Financial Officer of CIS Investments, Inc.
(CISI), a General Partner of IDS Managed Futures II, L.P. (the
Partnership), and I, James A. Davison, the President of CISI,
certify that (i) the attached 10-Q fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the
information contained in the attached Form 10-Q fairly presents, in all material
respects, the financial condition and results of operations of the Partnership.

| |                                                                                  
| | ---------------------------------------------------------------------------------
| | James A. Davison
     President
     CIS Investments, Inc.
     November 12, 2002

| |                                                                                                
| | -----------------------------------------------------------------------------------------------
| | Shawn D. O'Brien
     Chief Financial Officer
     CIS Investments, Inc.
     November 12, 2002
§ 522.1696a Penicillin G benzathine and penicillin G procaine suspension. ( a ) *Specifications.* Each milliliter of aqueous suspension contains penicillin G benzathine and penicillin G procaine, each equivalent to 150,000 units of penicillin G.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for the conditions of use in paragraph (d) of this section as follows: ( 1 ) Nos. 054771 and 061133 for use as in paragraph (d)(1) of this section.
( 2 ) Nos. 016592 and 061133 for use as in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(2)(iii) of this section.
( 3 ) No. 054771 for use as in paragraphs (d)(2)(i), (d)(2)(ii)(B), and (d)(2)(iii) of this section.
( c ) *Related tolerances.* See § 556.510 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Horses, dogs, and beef cattle* — ( i ) *Amount* — ( A ) *Beef cattle.* 2 milliliters per 150 pounds of body weight intramuscularly or subcutaneously. Repeat dosage in 48 hours.
( B ) *Horses.* 2 milliliters per 150 pounds of body weight intramuscularly. Repeat dosage in 48 hours.
( C ) *Dogs.* 1 milliliter per 10 to 25 pounds of body weight intramuscularly or subcutaneously. Repeat dosage in 48 hours.
( ii ) *Indications for use.* Treatment of bacterial infections susceptible to penicillin G.
( iii ) *Limitations.* Not for use in beef cattle within 30 days of slaughter. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Beef cattle* — ( i ) *Amount.* 2 milliliters per 150 pounds of body weight subcutaneously. Repeat dosage in 48 hours.
( ii ) *Indications for use.* ( A ) Treatment of bacterial pneumonia (*Streptococcus* spp., *Actinomyces pyogenes*, *Staphylococcus aureus*); upper respiratory infections such as rhinitis or pharyngitis (*A. pyogenes*); blackleg (*Clostridium chauvoei*).
( B ) As in paragraph (d)(2)(ii)(A) of this section; and prophylaxis of bovine shipping fever in 300- to 500-pound beef calves.
( iii ) *Limitations.* Not for use within 30 days of slaughter. For No. 016592: A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. For No. 016592: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[66 FR 711, Jan. 4, 2001, as amended at 68 FR 34534, June 10, 2003; 70 FR 21947, Apr. 28, 2005; 70 FR 50182, Aug. 26, 2005; 73 FR 16754, Mar. 31, 2008; 75 FR 54017, Sept. 3, 2010; 77 FR 4897, Feb. 1, 2012; 78 FR 17597, Mar. 22, 2013; 79 FR 16192, Mar. 25, 2014; 81 FR 22524, Apr. 18, 2016; 84 FR 8974, Mar. 13, 2019; 85 FR 18120, Apr. 1, 2020; 88 FR 16548, Mar. 20, 2023]
Exhibit 99.1

                        Letterhead of Jeffrey A. Lipsitz

Board of Directors
BrandPartners
777 Third Avenue
30th floor
New York, NY 10021

Gentlemen:

The purpose of this letter is to inform you that I am resigning from the Board
of Directors effective immediately. This is a result of recent commitments that
make it impossible for me to devote the necessary time to this endeavor.

It had been a pleasure to serve with you and I wish you all the best of luck in
the future.

Sincerely,

/s/ Jeffrey A. Lipsitz
----------------------
Jeffrey A. Lipsitz
#### § 601.30 Scope.

This subpart applies to radiopharmaceuticals intended for in vivo administration for diagnostic and monitoring use. It does not apply to radiopharmaceuticals intended for therapeutic purposes. In situations where a particular radiopharmaceutical is proposed for both diagnostic and therapeutic uses, the radiopharmaceutical must be evaluated taking into account each intended use.
EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CEC Entertainment, Inc. (the Company) on Form 10-Q for the quarter ended July 1, 2007 as
filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned certifies to his knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods
presented in the Report.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



/s/ Christopher D. MorrisChristopher D. MorrisChief Financial OfficerAugust 9, 2007


A signed original of this written statement required by Section 906 has been provided to CEC
Entertainment, Inc. and will be retained by CEC Entertainment, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
FORM 10-Q

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

(X)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2007

 

OR

 

( )  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from  to ____

 

Commission file number 000-21644

 

**CRIMSON EXPLORATION INC.**

(Exact name of Registrant as specified in its charter)

 

| **Delaware**

(State or other jurisdiction of incorporation)                                   |   | **20-3037840**

(IRS Employer Identification No.) |
|------------------------------------------------------------------------------------------------|--------|---------------------------------------------------|
|                                                                                           |   |                                              |
| **717 Texas Avenue, Suite 2900**

**Houston, Texas**

(Address of principal executive offices) |   | **77002**

(zip code)                             |
|                                                                                           |   |                                              |

 

**(713) 236-7400**

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act.

 

| Large accelerated filer o |   | Accelerated filer o |   | Non-accelerated filer x |
|---------------------------|--------|---------------------|--------|-------------------------|

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No x

 

On November 9, 2007, there were 5,077,437 shares outstanding of the Registrant’s Common Stock, par value $0.001.

 

----